Dana-farber Cancer Institute

This phase 2 study tested a drug called GDC-0084 combined with trastuzumab (Herceptin) in 17 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the combination could shrink or control brain tumors. Unfortunately, the trial was terminated …

This study tested a drug called BVD-523 (Ulixertinib) in 13 people with advanced uveal melanoma, a rare eye cancer that has spread. The drug works by blocking certain proteins that help cancer grow. The trial was terminated early, so results are limited and it's unclear how well …

This study tested a drug called abemaciclib in 27 people with a specific type of advanced breast cancer (triple-negative, retinoblastoma-positive). The goal was to see if the drug could shrink tumors or slow the cancer's growth. The trial was terminated early, so results are limi…

This phase 2 trial tested the drug neratinib, alone or with fulvestrant, in 21 people with HER2-positive, ER-positive metastatic breast cancer. The study aimed to see if the combination could slow cancer growth. However, the trial was terminated early, meaning we have limited dat…

This study tested two immunotherapy drugs, ipilimumab and nivolumab, as a first treatment for people with advanced non-small cell lung cancer that had spread. The goal was to see how well the drugs worked and to find markers that predict response. Only 5 people enrolled before th…

This study tested two immunotherapy drugs, durvalumab and tremelimumab, in people with malignant pleural mesothelioma, a rare cancer of the lung lining. The trial enrolled 19 participants whose cancer had worsened after standard chemotherapy. The goal was to see if the drug combi…

This study tested whether adding the immunotherapy drug avelumab to standard radiation could help treat muscle-invasive bladder cancer in patients who cannot receive the usual chemotherapy. Fourteen participants received the combination therapy. The goal was to see if the cancer …